2023 universal registration document

5. 2023 Consolidated Financial Statements

5.5. Share subscription or purchase options – Free shares
Accounting principles

In accordance with the requirements of IFRS 2 “Share-based Payment”, the value of options or free shares granted as calculated at the grant date is expensed in the income statement over the vesting period, which is generally five years for purchase options and four years for free shares.

The fair value of free shares corresponds to the value of the share at the grant date, less dividends expected to be paid during the vesting period.

The impact of IFRS 2 on profit for the period is booked on the Selling, general and administrative expenses item of the income statement at Group level, and is not allocated to the Divisions or geographic zones.

a) Share subscription or purchase options

There is no option plans in force at 31 December 2023. Data concerning all share option plans during financial years 2023, 2022 and 2021 are set out below:

  31.12.2023 31.12.2022 31.12.2021
  Number of options Weighted average exercise price Number of option Weighted average exercise price Number of option Weighted average
exercise price
Number of options not exercised at beginning of period     57,397 €83.19
Options granted          
Options exercised         -52,397 €83.19
Options expired         -5,000  
Number of options not exercised at end of period      
Of which:      
number of exercisable options at end of period            
expired options at end of period            
Weighted average share price           €364.74
b) Free shares

The table below summarises the data on free share plans vesting after 1 January 2021.

Grant date Vesting date Number of shares granted Number of shares issued/allotted Number of shares not finally vested
STOCK SUBSCRIPTION PLANS STOCK SUBSCRIPTION PLANSVesting date

 

STOCK SUBSCRIPTION PLANSNumber of shares granted

 

STOCK SUBSCRIPTION PLANSNumber of shares issued/allotted

 

STOCK SUBSCRIPTION PLANSNumber of shares not finally vested

 

20.04.2017

20.04.2017

Vesting date

21.04.2021

20.04.2017

Number of shares granted

906,000

20.04.2017

Number of shares issued/allotted

742,276

20.04.2017

Number of shares not finally vested

17.04.2018

17.04.2018

Vesting date

18.04.2022

17.04.2018

Number of shares granted

931,000

17.04.2018

Number of shares issued/allotted

868,575

17.04.2018

Number of shares not finally vested

18.04.2019

18.04.2019

Vesting date

19.04.2023

18.04.2019

Number of shares granted

843,075

18.04.2019

Number of shares issued/allotted

776,975

18.04.2019

Number of shares not finally vested

14.10.2020

14.10.2020

Vesting date

15.10.2024

14.10.2020

Number of shares granted

713,660

14.10.2020

Number of shares issued/allotted

385

14.10.2020

Number of shares not finally vested

673,530

07.10.2021

07.10.2021

Vesting date

08.10.2025

07.10.2021

Number of shares granted

588,750

07.10.2021

Number of shares issued/allotted

105

07.10.2021

Number of shares not finally vested

570,685

13.10.2022

13.10.2022

Vesting date

14.10.2026

13.10.2022

Number of shares granted

700,000

13.10.2022

Number of shares issued/allotted

13.10.2022

Number of shares not finally vested

699,375

12.10.2023

12.10.2023

Vesting date

13.10.2027

12.10.2023

Number of shares granted

650,580

12.10.2023

Number of shares issued/allotted

12.10.2023

Number of shares not finally vested

650,580

For the conditional grant of shares, the plan provides for a four-year vesting period after which vesting is effective and final, subject to meeting the conditions of the plan.

The performance conditions apply to the 7 October 2021 and 14 October 2020 plans:

  • for 50% of shares granted, the growth in comparable Cosmetics sales in relation to growth in net sales for a panel of competitors:
    • 2022, 2023 and 2024 financial years under the 2021 plan,
    • 2021, 2022 and 2023 financial years under the 2020 plan;
  • for 50% of shares granted, the increase over the same period in the Group’s consolidated operating profit for the 7 October 2021. and